Corcept Therapeutics (CORT) Misses Q4 EPS by 12c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $107.50 -7.55%
Revenue Growth %: +56.0%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: +56.0%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.26, $0.12 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $181.89 million versus the consensus estimate of $198.05 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $900-950 million, versus the consensus of $855.1 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- CVB Financial (CVBF) Tops Q3 EPS by 3c
- Farmers & Merchants Bancorp, Inc. (FMAO) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
